Search results
Results from the WOW.Com Content Network
Off-label use is the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration. [1] Both prescription drugs and over-the-counter drugs (OTCs) can be used in off-label ways, although most studies of off-label use focus on prescription drugs.
Modafinil is a central nervous system (CNS) stimulant medication used to treat sleepiness due to narcolepsy, shift work sleep disorder, and obstructive sleep apnea. It is often used off-label as a nootropic. Prazosin (Minipress) for nightmares: prazosin is approved for the use of hypertension. A 2012 systematic review showed a small benefit for ...
Valaciclovir, also spelled valacyclovir, is an antiviral medication used to treat outbreaks of herpes simplex or herpes zoster (shingles). [2] It is also used to prevent cytomegalovirus following a kidney transplant in high risk cases. [2] It is taken by mouth. [2] Common side effects include headache and vomiting. [2]
While estimates vary, some studies suggest that 1 in 5 prescriptions of common medications involves an off-label use. Skip to main content. 24/7 Help. For premium support please call: 800-290 ...
Known off-label uses where doctors prescribe gabapentin include as a treatment for hot flashes, restless leg syndrome, mood disorders, anxiety, and to diminish nerve pain related to diabetes or ...
Used off-label to treat insomnia; Sonata – a non-benzodiazepine hypnotic; Spravato – a rapid-acting antidepressant of the NMDA receptor antagonist class; enantiomer of ketamine; Stelazine (trifluoperazine) – an antipsychotic used in the treatment of psychotic disorders, anxiety, and nausea caused by chemotherapy [2]
Other side effects may include infertility and kidney problems. [3] When used during pregnancy, it causes birth defects in some animals. [3] Valganciclovir is the L-valyl ester of ganciclovir and works when broken down into ganciclovir by the intestine and liver. [3] Valganciclovir was approved for medical use in 2001. [4]
2009 settlement for off-label uses promotions [ edit ] On September 2, 2009, the United States Department of Justice fined Pfizer $2.3 billion after one of its subsidiaries , Pharmacia & Upjohn Company, pleaded guilty to marketing four drugs, including Bextra, "with the intent to defraud or mislead."